News & Updates

Sulodexide and its multifaceted role in the multiverse of vascular diseases

[ Sulodexide Speakers Meeting ]

Speakers:

Gilbert C. Vilela, MD, FPCP, FPCC, FACC, FESC, FAsCC
Cardiologist
Examiner, Philippine Specialty Board of Cardiology
Past President, Philippine College of Cardiology
Former Deputy Executive Director for Education, Training and Research, Philippine Heart Center

Rosella S. Arellano, MD, FPCP, FPCC
Cardiologist, Adult Vascular Medicine Specialist
Past President, Philippine Society of Vascular Medicine
Training Officer, Clinical Research Fellowship in Vascular Medicine, Philippine Heart Center

Eugenio B. Reyes, MD, FPCP, FPCC, FACC
Cardiologist
Past Medical Director, Manila Doctors Hospital
Associate Professor, Department of Medicine, University of the Philippines – College of Medicine

Maria Honolina S. Gomez, MD, FPCP, FPCEDM, FACE
Endocrinologist
(Retired) Professor 5, University of Sto. Tomas Faculty of Medicine and Surgery
Past Chair, Philippine Board of Internal Medicine, Philippine College of Physicians


Vascular diseases are deeply interconnected, as blood flow sustains every part of the body. For over 25 years, sulodexide has played a pivotal role in improving patient outcomes across this complex landscape. On February 7, 2025, the Corbridge Group convened leading experts from various specialties to explore the latest theories, practices, and breakthroughs in vascular disease management, with a particular focus on the multifaceted benefits of sulodexide.

Apixaban (Eliquis): Superior anticoagulation efficacy with minimized bleeding risks

The coexistence of hypertension and dyslipidemia contributes to an increased risk of CVD, warranting efficient management strategies.

[ Dr Magno leads the first topic on evidence-based management of hypertension ]

Cardiovascular diseases (CVD) are the leading cause of death globally, with hypertension and dyslipidemia as major modifiable risk factors. The coexistence of hypertension and dyslipidemia contributes to an increased risk of CVD, warranting efficient management strategies.¹

On February 27, 2025, at the 30th joint convention of the Philippine Society of Hypertension and Philippine Lipid and Atherosclerosis Society, Servier Philippines hosted a lunch symposium led by Dr Jose Donato Magno and Dr Ma. Cecille Cruz. They presented current evidence and evolving approaches in managing clinical scenarios in patients with both hypertension and dyslipidemia.

Eliquis transforms anticoagulation approaches in stroke and systemic embolism

Product Highlight - Dapagliflozin (Glifixy)

Film-coated tablet 10 mg

Unleashing Innovation and Updates in Clinical Practice.

On October 25, 2024, gastroenterologists and hepatologists gathered at the Globe Auditorium, BGC braving the raging typhoon to listen to top experts talk about updates in clinical practice in managing liver disease. This was the second installment of a 2-day lecture series sponsored by Opella Healthcare Philippines.

Golden Liver Health Forum: Multidisciplinary Approaches to Cardiometabolic and Liver Disease Management

The Golden Liver Health Forum, convened on October 24, 2024, at the Globe Auditorium in BGC, presented evolving multi-disciplinary strategies in managing Metabolic Associated Fatty Liver Disease (MAFLD). Through insightful discussions from top experts in endocrinology, cardiology, and hepatology—Bien Matawaran, MD, Louella Santos, MD, and Stephen Wong, MD, chaired by Prof Jose D. Sollano Jr., MD, the forum provided clinicians with valuable, patient-centered strategies that enhance risk assessment and management for these intertwined health concerns.

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.